BNP Paribas Asset Management
AMRX icon

BNP Paribas Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

BNP Paribas Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.5K Buy
2,224
+634
+40% +$8.69K ﹤0.01% 1851
2026
Q1 		$19.8K Buy
1,590
+169
+12% +$2.27K ﹤0.01% 2036
2025
Q4 		$18K Buy
1,421
+452
+47% +$5.17K ﹤0.01% 1978
2025
Q3 		$10K Sell
969
-298
-24% -$2.67K ﹤0.01% 1618
2025
Q2 		$10K Buy
+1,267
New +$9.55K ﹤0.01% 1756

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

BNP Paribas Asset Management's AMRX Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Amneal Pharmaceuticals (AMRX) stake by 40% in Q2 2026, buying an estimated $8.69K and bringing the position to 2,224 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1851.

BNP Paribas Asset Management first reported a position in AMRX in Q2 2025 and has held it in 5 quarters since. 235 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • BNP Paribas Asset Management held 2,224 shares of Amneal Pharmaceuticals worth $38.5K as of Q2 2026.
  • BNP Paribas Asset Management bought 634 Amneal Pharmaceuticals shares in Q2 2026, an estimated $8.69K.
  • Amneal Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1851 holding.
  • BNP Paribas Asset Management first reported a position in Amneal Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 235 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.